Abbvie ((ABBV)), Genmab (Otc) ((GMAB)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The recent clinical study update from AbbVie and Genmab focuses on the safety and preliminary efficacy of Epcoritamab in Japanese patients with relapsed or refractory B-cell Non-Hodgkin Lymphoma (B-NHL). Officially titled ‘Safety and Preliminary Efficacy of Epcoritamab (GEN3013; DuoBody®-CD3×CD20) in Japanese Subjects With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma,’ this Phase 1/2 trial aims to determine the maximum tolerated dose and recommended Phase-2 dose, while establishing the safety profile of Epcoritamab.
The intervention being tested is Epcoritamab, a biological treatment administered either as monotherapy or in combination with standard of care (SOC) chemotherapy. The study explores various regimens, including Epcoritamab combined with Rituximab and Lenalidomide, and other chemotherapy agents.
The study design is interventional, non-randomized, and follows a sequential assignment model in Phase 1, transitioning to a parallel group assignment in Phase 2. There is no masking involved, and the primary purpose is treatment.
Key dates include the actual start date of August 20, 2020, with the last update submitted on August 4, 2025. These dates are crucial for tracking the study’s progress and timeline.
The market implications of this study update could be significant for AbbVie and Genmab, potentially influencing their stock performance and investor sentiment. As this study progresses, it could position these companies favorably in the competitive landscape of lymphoma treatments.
The study is ongoing, with further details available on the ClinicalTrials portal.